Ignite Creation Date:
2024-05-06 @ 1:21 PM
Last Modification Date:
2024-10-26 @ 1:13 PM
Study NCT ID:
NCT04009317
Status:
UNKNOWN
Last Update Posted:
2019-10-30
First Post:
2019-07-02
Brief Title:
Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase ALK Positive Non-Small Cell Lung Cancer NSCLC
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Organization:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-08-13
Start Date Type:
ACTUAL
Primary Completion Date:
2021-10-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-04-30
Completion Date Type:
ESTIMATED
First Submit Date:
2019-07-02
First Submit QC Date:
July 2 2019
Study First Post Date:
2019-07-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-10-29
Last Update Post Date:
2019-10-30
Last Update Post Date Type:
ACTUAL